Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 424 entries
Sorted by: Best Match Show Resources per page
Two cases of long-acting paliperidone in adolescence.

Therapeutic advances in psychopharmacology

Fàbrega M, Sugranyes G, Baeza I.
PMID: 26557986
Ther Adv Psychopharmacol. 2015 Oct;5(5):304-6. doi: 10.1177/2045125315600141.

Paliperidone palmitate long-acting injection (PPLAI) is an atypical antipsychotic agent currently approved by the European Medicine Agency for the acute and maintenance treatment of schizophrenia in adults. However, there is no information so far on safety and effectiveness in...

Cite
Fàbrega M, Sugranyes G, Baeza I. Two cases of long-acting paliperidone in adolescence. Ther Adv Psychopharmacol. 2015;5(5):304-6doi: 10.1177/2045125315600141.
Fàbrega, M., Sugranyes, G., & Baeza, I. (2015). Two cases of long-acting paliperidone in adolescence. Therapeutic advances in psychopharmacology, 5(5), 304-6. https://doi.org/10.1177/2045125315600141
Fàbrega, Marina, et al. "Two cases of long-acting paliperidone in adolescence." Therapeutic advances in psychopharmacology vol. 5,5 (2015): 304-6. doi: https://doi.org/10.1177/2045125315600141
Fàbrega M, Sugranyes G, Baeza I. Two cases of long-acting paliperidone in adolescence. Ther Adv Psychopharmacol. 2015 Oct;5(5):304-6. doi: 10.1177/2045125315600141. PMID: 26557986; PMCID: PMC4622123.
Copy Download .nbib Format: NLM
Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials.

Therapeutic advances in psychopharmacology

Praharaj SK, Kongasseri S, Behere RV, Sharma PS.
PMID: 26557987
Ther Adv Psychopharmacol. 2015 Oct;5(5):307-13. doi: 10.1177/2045125315601343.

OBJECTIVE: To conduct a systematic review and meta-analysis of randomized placebo-controlled trials of mirtazapine for the treatment of antipsychotic-induced acute akathisia (AIAA).METHODS: Studies were identified using online searches of PUBMED/MEDLINE and Cochrane database (CENTRAL), along with websites recording trial...

Cite
Praharaj SK, Kongasseri S, Behere RV, et al. Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol. 2015;5(5):307-13doi: 10.1177/2045125315601343.
Praharaj, S. K., Kongasseri, S., Behere, R. V., & Sharma, P. S. (2015). Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Therapeutic advances in psychopharmacology, 5(5), 307-13. https://doi.org/10.1177/2045125315601343
Praharaj, Samir Kumar, et al. "Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials." Therapeutic advances in psychopharmacology vol. 5,5 (2015): 307-13. doi: https://doi.org/10.1177/2045125315601343
Praharaj SK, Kongasseri S, Behere RV, Sharma PS. Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol. 2015 Oct;5(5):307-13. doi: 10.1177/2045125315601343. PMID: 26557987; PMCID: PMC4622124.
Copy Download .nbib Format: NLM
Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?.

Therapeutic advances in psychopharmacology

Niolu C, Bianciardi E, Di Lorenzo G, Marchetta C, Barone Y, Sterbini N, Ribolsi M, Reggiardo G, Siracusano A.
PMID: 26557984
Ther Adv Psychopharmacol. 2015 Oct;5(5):278-88. doi: 10.1177/2045125315596897.

AIM: This study evaluated adherence to treatment, quality of life and subjective well-being in patients with psychosis treated with long-acting injectable risperidone. Subjects enrolled were part of a larger study where patients were observed in an adherence to treatment...

Cite
Niolu C, Bianciardi E, Di Lorenzo G, et al. Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?. Ther Adv Psychopharmacol. 2015;5(5):278-88doi: 10.1177/2045125315596897.
Niolu, C., Bianciardi, E., Di Lorenzo, G., Marchetta, C., Barone, Y., Sterbini, N., Ribolsi, M., Reggiardo, G., & Siracusano, A. (2015). Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?. Therapeutic advances in psychopharmacology, 5(5), 278-88. https://doi.org/10.1177/2045125315596897
Niolu, Cinzia, et al. "Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?." Therapeutic advances in psychopharmacology vol. 5,5 (2015): 278-88. doi: https://doi.org/10.1177/2045125315596897
Niolu C, Bianciardi E, Di Lorenzo G, Marchetta C, Barone Y, Sterbini N, Ribolsi M, Reggiardo G, Siracusano A. Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?. Ther Adv Psychopharmacol. 2015 Oct;5(5):278-88. doi: 10.1177/2045125315596897. PMID: 26557984; PMCID: PMC4622121.
Copy Download .nbib Format: NLM
Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series.

Therapeutic advances in psychopharmacology

Aksoy Poyraz C, Turan Ş, Demirel ÖF, Usta Sağlam NG, Yıldız N, Duran A.
PMID: 26301080
Ther Adv Psychopharmacol. 2015 Aug;5(4):237-42. doi: 10.1177/2045125315584871.

Treatment of severe and refractory manic episodes in hospital settings can occasionally be very difficult. In particular, severely excited patients showing aggressive, hostile, impulsive behaviours frequently require physical restraint and seclusion, high doses of antipsychotics and benzodiazepines, and sometimes,...

Cite
Aksoy Poyraz C, Turan Ş, Demirel ÖF, et al. Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series. Ther Adv Psychopharmacol. 2015;5(4):237-42doi: 10.1177/2045125315584871.
Aksoy Poyraz, C., Turan, �. �., Demirel, �. �. F., Usta Sağlam, N. G., Yıldız, N., & Duran, A. (2015). Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series. Therapeutic advances in psychopharmacology, 5(4), 237-42. https://doi.org/10.1177/2045125315584871
Aksoy Poyraz, Cana, et al. "Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series." Therapeutic advances in psychopharmacology vol. 5,4 (2015): 237-42. doi: https://doi.org/10.1177/2045125315584871
Aksoy Poyraz C, Turan Ş, Demirel ÖF, Usta Sağlam NG, Yıldız N, Duran A. Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series. Ther Adv Psychopharmacol. 2015 Aug;5(4):237-42. doi: 10.1177/2045125315584871. PMID: 26301080; PMCID: PMC4535045.
Copy Download .nbib Format: NLM
MDMA for the treatment of mood disorder: all talk no substance?.

Therapeutic advances in psychopharmacology

Patel R, Titheradge D.
PMID: 26199721
Ther Adv Psychopharmacol. 2015 Jun;5(3):179-88. doi: 10.1177/2045125315583786.

BACKGROUND: Unipolar depression is the third highest contributor to the global burden of disease, yet current pharmacotherapies typically take about 6 weeks to have an effect. A rapid-onset agent is an attractive prospect, not only to alleviate symptoms before...

Cite
Patel R, Titheradge D. MDMA for the treatment of mood disorder: all talk no substance?. Ther Adv Psychopharmacol. 2015;5(3):179-88doi: 10.1177/2045125315583786.
Patel, R., & Titheradge, D. (2015). MDMA for the treatment of mood disorder: all talk no substance?. Therapeutic advances in psychopharmacology, 5(3), 179-88. https://doi.org/10.1177/2045125315583786
Patel, Rachel, and Titheradge, Daniel. "MDMA for the treatment of mood disorder: all talk no substance?." Therapeutic advances in psychopharmacology vol. 5,3 (2015): 179-88. doi: https://doi.org/10.1177/2045125315583786
Patel R, Titheradge D. MDMA for the treatment of mood disorder: all talk no substance?. Ther Adv Psychopharmacol. 2015 Jun;5(3):179-88. doi: 10.1177/2045125315583786. PMID: 26199721; PMCID: PMC4502590.
Copy Download .nbib Format: NLM
Lactate in the brain: an update on its relevance to brain energy, neurons, glia and panic disorder.

Therapeutic advances in psychopharmacology

Riske L, Thomas RK, Baker GB, Dursun SM.
PMID: 28255438
Ther Adv Psychopharmacol. 2017 Feb;7(2):85-89. doi: 10.1177/2045125316675579. Epub 2016 Oct 28.

Lactate is considered an important metabolite in the human body, but there has been considerable debate about its roles in brain function. Research in recent years has suggested that lactate from astrocytes may be crucial for supporting axonal function,...

Cite
Riske L, Thomas RK, Baker GB, et al. Lactate in the brain: an update on its relevance to brain energy, neurons, glia and panic disorder. Ther Adv Psychopharmacol. 2016;7(2):85-89doi: 10.1177/2045125316675579.
Riske, L., Thomas, R. K., Baker, G. B., & Dursun, S. M. (2017). Lactate in the brain: an update on its relevance to brain energy, neurons, glia and panic disorder. Therapeutic advances in psychopharmacology, 7(2), 85-89. https://doi.org/10.1177/2045125316675579
Riske, Laurel, et al. "Lactate in the brain: an update on its relevance to brain energy, neurons, glia and panic disorder." Therapeutic advances in psychopharmacology vol. 7,2 (2017): 85-89. doi: https://doi.org/10.1177/2045125316675579
Riske L, Thomas RK, Baker GB, Dursun SM. Lactate in the brain: an update on its relevance to brain energy, neurons, glia and panic disorder. Ther Adv Psychopharmacol. 2017 Feb;7(2):85-89. doi: 10.1177/2045125316675579. Epub 2016 Oct 28. PMID: 28255438; PMCID: PMC5315230.
Copy Download .nbib Format: NLM
Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit.

Therapeutic advances in psychopharmacology

Gee SH, Taylor DM, Shergill SS, Flanagan R, MacCabe JH.
PMID: 28255437
Ther Adv Psychopharmacol. 2017 Feb;7(2):79-83. doi: 10.1177/2045125316677027. Epub 2016 Dec 02.

BACKGROUND: Tobacco smoke is known to affect plasma levels of some drugs, including the antipsychotic clozapine. The effects of suddenly stopping smoking on patients who take clozapine can be severe, as plasma concentrations are expected to rapidly rise, potentially...

Cite
Gee SH, Taylor DM, Shergill SS, et al. Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit. Ther Adv Psychopharmacol. 2016;7(2):79-83doi: 10.1177/2045125316677027.
Gee, S. H., Taylor, D. M., Shergill, S. S., Flanagan, R., & MacCabe, J. H. (2017). Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit. Therapeutic advances in psychopharmacology, 7(2), 79-83. https://doi.org/10.1177/2045125316677027
Gee, Siobhan H, et al. "Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit." Therapeutic advances in psychopharmacology vol. 7,2 (2017): 79-83. doi: https://doi.org/10.1177/2045125316677027
Gee SH, Taylor DM, Shergill SS, Flanagan R, MacCabe JH. Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit. Ther Adv Psychopharmacol. 2017 Feb;7(2):79-83. doi: 10.1177/2045125316677027. Epub 2016 Dec 02. PMID: 28255437; PMCID: PMC5315231.
Copy Download .nbib Format: NLM
Clozapine prescribing in the UK: views and experience of consultant psychiatrists.

Therapeutic advances in psychopharmacology

Tungaraza TE, Farooq S.
PMID: 26240748
Ther Adv Psychopharmacol. 2015 Apr;5(2):88-96. doi: 10.1177/2045125314566808.

OBJECTIVES: It has been repeatedly shown that clozapine is underutilized and there is delayed use of it in clinical practice.METHOD: An online survey was sent to 2771 consultant psychiatrists registered with the Royal College of Psychiatrists in the UK....

Cite
Tungaraza TE, Farooq S. Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol. 2015;5(2):88-96doi: 10.1177/2045125314566808.
Tungaraza, T. E., & Farooq, S. (2015). Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Therapeutic advances in psychopharmacology, 5(2), 88-96. https://doi.org/10.1177/2045125314566808
Tungaraza, Tongeji E, and Farooq, Saeed. "Clozapine prescribing in the UK: views and experience of consultant psychiatrists." Therapeutic advances in psychopharmacology vol. 5,2 (2015): 88-96. doi: https://doi.org/10.1177/2045125314566808
Tungaraza TE, Farooq S. Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol. 2015 Apr;5(2):88-96. doi: 10.1177/2045125314566808. PMID: 26240748; PMCID: PMC4521444.
Copy Download .nbib Format: NLM
Legal highs: staying on top of the flood of novel psychoactive substances.

Therapeutic advances in psychopharmacology

Baumeister D, Tojo LM, Tracy DK.
PMID: 26240749
Ther Adv Psychopharmacol. 2015 Apr;5(2):97-132. doi: 10.1177/2045125314559539.

There has been growing clinical, public, and media awareness and concern about the availability and potential harmfulness of so-called 'legal highs', which are more appropriately called new or novel psychoactive substances (NPS). A cat-and-mouse process has emerged wherein unknown...

Cite
Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol. 2015;5(2):97-132doi: 10.1177/2045125314559539.
Baumeister, D., Tojo, L. M., & Tracy, D. K. (2015). Legal highs: staying on top of the flood of novel psychoactive substances. Therapeutic advances in psychopharmacology, 5(2), 97-132. https://doi.org/10.1177/2045125314559539
Baumeister, David, et al. "Legal highs: staying on top of the flood of novel psychoactive substances." Therapeutic advances in psychopharmacology vol. 5,2 (2015): 97-132. doi: https://doi.org/10.1177/2045125314559539
Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol. 2015 Apr;5(2):97-132. doi: 10.1177/2045125314559539. PMID: 26240749; PMCID: PMC4521440.
Copy Download .nbib Format: NLM
Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial.

Therapeutic advances in psychopharmacology

Shoja Shafti S, Azizi Khoei A.
PMID: 27721970
Ther Adv Psychopharmacol. 2016 Oct;6(5):308-316. doi: 10.1177/2045125316656334. Epub 2016 Sep 14.

BACKGROUND: Several lines of evidence suggest that the cholinergic system may be disrupted in schizophrenia and so this may contribute to the cognitive impairments of schizophrenic patients. Because such deficits do not respond to neuroleptic treatment, different approaches have...

Cite
Shoja Shafti S, Azizi Khoei A. Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. Ther Adv Psychopharmacol. 2016;6(5):308-316doi: 10.1177/2045125316656334.
Shoja Shafti, S., & Azizi Khoei, A. (2016). Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. Therapeutic advances in psychopharmacology, 6(5), 308-316. https://doi.org/10.1177/2045125316656334
Shoja Shafti, Saeed, and Azizi Khoei, Abbas. "Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial." Therapeutic advances in psychopharmacology vol. 6,5 (2016): 308-316. doi: https://doi.org/10.1177/2045125316656334
Shoja Shafti S, Azizi Khoei A. Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. Ther Adv Psychopharmacol. 2016 Oct;6(5):308-316. doi: 10.1177/2045125316656334. Epub 2016 Sep 14. PMID: 27721970; PMCID: PMC5036138.
Copy Download .nbib Format: NLM
Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review.

Therapeutic advances in psychopharmacology

Hutchison SL, Ghuman JK, Ghuman HS, Karpov I, Schuster JM.
PMID: 27721971
Ther Adv Psychopharmacol. 2016 Oct;6(5):317-334. doi: 10.1177/2045125316647686. Epub 2016 May 20.

Attention-deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed mental health disorders and is associated with higher incidence of comorbid oppositional or conduct, mood, anxiety, pervasive developmental, and substance-use disorders. Comorbid mental health conditions may alter the...

Cite
Hutchison SL, Ghuman JK, Ghuman HS, et al. Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. Ther Adv Psychopharmacol. 2016;6(5):317-334doi: 10.1177/2045125316647686.
Hutchison, S. L., Ghuman, J. K., Ghuman, H. S., Karpov, I., & Schuster, J. M. (2016). Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. Therapeutic advances in psychopharmacology, 6(5), 317-334. https://doi.org/10.1177/2045125316647686
Hutchison, Shari L, et al. "Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review." Therapeutic advances in psychopharmacology vol. 6,5 (2016): 317-334. doi: https://doi.org/10.1177/2045125316647686
Hutchison SL, Ghuman JK, Ghuman HS, Karpov I, Schuster JM. Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. Ther Adv Psychopharmacol. 2016 Oct;6(5):317-334. doi: 10.1177/2045125316647686. Epub 2016 May 20. PMID: 27721971; PMCID: PMC5036135.
Copy Download .nbib Format: NLM
Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma.

Therapeutic advances in psychopharmacology

Usta NG, Poyraz CA, Aktan M, Duran A.
PMID: 25489479
Ther Adv Psychopharmacol. 2014 Dec;4(6):276-81. doi: 10.1177/2045125314553610.

BACKGROUND: Clozapine remains the antipsychotic of choice for refractory schizophrenia. Given the particular side effects of clozapine including neutropenia and myelosuppression, safety and efficacy of add-on chemotherapy for patients who are already under clozapine treatment remain unknown.OBJECTIVE: We present...

Cite
Usta NG, Poyraz CA, Aktan M, et al. Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma. Ther Adv Psychopharmacol. 2014;4(6):276-81doi: 10.1177/2045125314553610.
Usta, N. G., Poyraz, C. A., Aktan, M., & Duran, A. (2014). Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma. Therapeutic advances in psychopharmacology, 4(6), 276-81. https://doi.org/10.1177/2045125314553610
Usta, Nazife Gamze, et al. "Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma." Therapeutic advances in psychopharmacology vol. 4,6 (2014): 276-81. doi: https://doi.org/10.1177/2045125314553610
Usta NG, Poyraz CA, Aktan M, Duran A. Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma. Ther Adv Psychopharmacol. 2014 Dec;4(6):276-81. doi: 10.1177/2045125314553610. PMID: 25489479; PMCID: PMC4257985.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 424 entries